Freshfields advises AstraZeneca in its acquisition of Fusion

Freshfields advised AstraZeneca in its acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, worth up to $2.4 billion. The acquisition is a significant step in the company’s ambition to transform cancer treatment with more targeted therapies.

The Freshfields team is led by corporate/M&A partner Sebastian L. Fain and counsel Oliver J. Board and associates Ryan Taylor, Joyce Yeo, Clara Barnosky and Ornia Abdouljalil. Partner Vinita Kailasanath and associates Sora Park and Jake Silvers advised on life sciences matters; partner Nicole Foster, counsel Jordan Salzman, senior associate Andrew Leeds and associate Chaim Leggiere advised on executive compensation and benefits matters; partners Claude Stansbury and associate Hannah Golden advised on tax matters; counsel Jeremiah Nelson and associate Casey Hagen advised on real estate matters; partner Kyle Lakin and associate Hadar Tanne advised on finance matters; partners Justin Stewart-Teitelbaum and Jenny Leahy, counsel Laura Onken, senior associate Sam Fulliton and associates Kirsty Brown and Hattie Van Metre advised on competition matters; partner Stephanie Brown Cripps and associate Photeine Lambridis advised on regulatory compliance matters; and partner Aimen Mir and CFIUS Advisor Colin Costello advised on foreign investment and national security matters. Blake, Cassels & Graydon LLP advised on Canadian law matters.

Learn more about this transaction here.